Russell G. Greig Appointed as Chairman of Syntaxin

By Syntaxin, PRNE
Wednesday, January 5, 2011

OXFORD, England, January 6, 2011 - Syntaxin, a biotechnology company developing novel biopharmaceuticals to
control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been
appointed as Chairman with immediate effect.

In joining Syntaxin, Dr. Greig brings with him over 30 years experience
in the pharmaceutical industry, with knowledge and expertise in research and
development, business development and commercial operations. Prior to joining
the company, Dr. Greig was President of SR One, GSK's Corporate Venture

Dr. Greig spent the majority of his career at GlaxoSmithKline, where he
held a number of positions including GSK's President of Pharmaceuticals
International from 2003-2008 and Senior Vice President Worldwide in Business
Development for R&D.

Dr Greig joined GSK in 1980 in the Discovery Unit of R&D and continued to
progressively hold positions of responsibility with R&D over the next three
decades. Dr Greig served as the Vice President and Director of Advanced
Technologies in Genetics from 1993 to 1996, with special responsibility for
managing collaborations with The Institute of Genomic Research and Human
Genome Sciences. In this position, he played a central role in managing
SmithKline Beecham's scientific and commercial relationship with Human Genome
Sciences and TIGR and extending its network of genomic alliances to other
pharmaceutical companies.

Since 2009, Dr. Greig has been a Director at Rib-X Pharmaceuticals; and a
Director and Executive Chairman at Anaphore Inc. since June 2010. Dr Greig
also serves as a Director at Genocea Biosciences, Inc and sits on the Board
of Edinburgh BioQuarter Commercialisation Advisory Group. Dr. Greig holds a
Bachelor of Science and Ph.D. in Biochemistry from the University of
Manchester, England and was a Fulbright Scholar.

Commenting on Dr Russell Greig's appointment, Dr Melanie Lee, Chief
Executive Officer of Syntaxin, said: "I'd like to thank Andrew Sandham, who
has been Chairman since the founding of Syntaxin five years ago, for his
considerable contribution to the growth, development and success of the
Company to date. Syntaxin is now at a transformational stage of its
development. Russell's knowledge and experience, working with both big pharma
companies and in supporting high growth emerging companies will be invaluable
in maximising the potential of our innovative technology platform."

Dr. Greig said: "I look forward to joining Syntaxin as it
enters a new stage in its growth strategy. Syntaxin has a novel technology
platform with great potential. The recent fundraising established strong
foundations for this exciting company. The commitment of its returning
investors and the joining of new corporate investors is a testament to the
quality of Syntaxin's management, business strategy and technology. I look
forward to working with Melanie and the management team to maximise the value
of Syntaxin's portfolio and technology platform.''

About Syntaxin (

Syntaxin discovers and develops a new class of
biopharmaceuticals which treat disease through selective inhibition of cell
secretory processes. It is developing cell secretion inhibitors for the
treatment of a range of endocrine diseases, including acromegaly.

Syntaxin's new Executive Management, appointed in February 2010, brings a
wealth of industry experience to the Company. Chief Executive Officer, Dr
Melanie Lee, spent a decade in research with GlaxoSmithKline and subsequently
held leadership positions at Celltech and UCB. Chief Business Officer, Dr
Nigel Clark, was formerly Vice President Business Development with Vernalis
and has a strong track record in building strategic alliances. Dr John Court,
Chief Development Officer, was previously founder and CEO of Fulcrum Pharma,
an international contract drug development business, following R&D roles at
Roche and Wellcome.

Syntaxin was founded in late 2005 through a spinout of intellectual
property and scientists from the Health Protection Agency a UK government
agency tasked with protecting human health, and benefits from 15 years of
research in the field of bacterial toxin engineering. The company owns
dominant patents and know how in the design, manufacture and use of novel
cell TSI based on engineered botulinum toxins. It has established a strong IP
base with over 50 granted patents covering the platform and products. It is
backed by a blue chip investor base including: Abingworth, Lundbeckfond
Ventures, LSP, Ipsen, JJDC, Quest, Seventure, and SR One.

Syntaxin's Targeted Secretion Inhibitors (TSI) technology

Syntaxin's TSI products are biological molecules synthesized in microbial
cell culture, which selectively bind to their chosen targeted cells and
become internalised to deliver endopeptidases into the cell's cytoplasm,
preventing further vesicular secretion. A single dose provides an extended
duration of action from weeks to months.

    Contact Details

    Syntaxin Ltd
    Melanie Lee, Nigel Clark
    Tel: +44(0)1235-552161


    Capital MS&L
    Mary Clark, Justine Lamond & Hollie Vile
    Tel: +44(0)20-7307-5337

Contact Details: Syntaxin Ltd, Melanie Lee, Nigel Clark, Tel: +44(0)1235-552161, Email: Melanie.lee at ; Media: Capital MS&L, Mary Clark, Justine Lamond & Hollie Vile, Tel: +44(0)20-7307-5337, Email:Syntaxin at

will not be displayed